Enlivex Therapeutics Valuation
| ENLV Stock | USD 1.07 0.14 15.05% |
Today, the firm appears to be undervalued. Enlivex Therapeutics shows a prevailing Real Value of $3.78 per share. The current price of the firm is $1.07. Our model computes the value of Enlivex Therapeutics from reviewing the firm fundamentals such as Shares Owned By Insiders of 5.73 %, shares owned by institutions of 18.80 %, and Current Valuation of (5.21 M) as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Enlivex Therapeutics' valuation include:
Price Book 0.6965 | Enterprise Value -5.2 M | Enterprise Value Ebitda (1.49) |
Undervalued
Today
Please note that Enlivex Therapeutics' price fluctuation is risky at this time. Calculation of the real value of Enlivex Therapeutics is based on 3 months time horizon. Increasing Enlivex Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Enlivex stock is determined by what a typical buyer is willing to pay for full or partial control of Enlivex Therapeutics. Since Enlivex Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Enlivex Stock. However, Enlivex Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.07 | Real 3.78 | Target 12.0 | Hype 1.1 | Naive 0.92 |
The intrinsic value of Enlivex Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Enlivex Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Enlivex Therapeutics helps investors to forecast how Enlivex stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Enlivex Therapeutics more accurately as focusing exclusively on Enlivex Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Enlivex Therapeutics' intrinsic value based on its ongoing forecasts of Enlivex Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Enlivex Therapeutics' closest peers.
Enlivex Therapeutics Cash |
|
Enlivex Valuation Trend
Analysing the historical paterns of Enlivex Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Enlivex Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Enlivex Therapeutics Total Value Analysis
Enlivex Therapeutics is currently expected to have valuation of (5.21 M) with market capitalization of 19.89 M, debt of 1.03 M, and cash on hands of 62.48 M. The negative valuation of Enlivex Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Enlivex Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(5.21 M) | 19.89 M | 1.03 M | 62.48 M |
Enlivex Therapeutics Asset Utilization
One of the ways to look at asset utilization of Enlivex is to check how much profit was generated for every dollar of assets it reports. Enlivex Therapeutics shows a negative utilization of assets of -0.27 percent, losing $0.002746 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Enlivex Therapeutics shows how discouraging it operates for each dollar spent on its assets.Enlivex Therapeutics Ownership Allocation
Enlivex Therapeutics holds a total of 21.41 Million outstanding shares. Enlivex Therapeutics shows 5.73 percent of its outstanding shares held by insiders and 18.8 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Enlivex Therapeutics Profitability Analysis
Net Loss for the year was (29.07 M) with profit before overhead, payroll, taxes, and interest of 0.About Enlivex Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Enlivex Therapeutics. We calculate exposure to Enlivex Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Enlivex Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -835 K | -793.2 K | |
| Pretax Profit Margin | (4.67) | (4.91) | |
| Operating Profit Margin | (3.87) | (4.06) | |
| Net Loss | (5.48) | (5.75) | |
| Gross Profit Margin | 0.79 | 0.70 |
Enlivex Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Enlivex Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 18.6 M |
Enlivex Therapeutics Current Valuation Indicators
Enlivex Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Enlivex Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Enlivex Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Enlivex Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Enlivex Therapeutics' worth.Additional Tools for Enlivex Stock Analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.